DOI QR코드

DOI QR Code

Efficacy and Safety of Topical Application of Epidermal Growth Factor (EGF) for Korean Acne Patient

한국인 여드름 환자에서 표피성장인자가 함유된 외용제의 피부 적용에 대한 유효성 및 안전성 평가

  • Suh, Joon Hyuk (Department of Dermatology, Chung-Ang University College of Medicine) ;
  • Hyun, Moo Yeol (Department of Dermatology, Chung-Ang University College of Medicine) ;
  • Jang, Seong Eum (Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choi, Sun Young (Department of Dermatology, Chung-Ang University College of Medicine) ;
  • Kim, Myeung Nam (Department of Dermatology, Chung-Ang University College of Medicine) ;
  • Kim, Beom Joon (Department of Dermatology, Chung-Ang University College of Medicine)
  • 서준혁 (중앙대학교 의과대학 피부과학교실) ;
  • 현무열 (중앙대학교 의과대학 피부과학교실) ;
  • 장성은 (울산대학교 의과대학 서울아산병원 피부과학교실) ;
  • 최선영 (중앙대학교 의과대학 피부과학교실) ;
  • 김명남 (중앙대학교 의과대학 피부과학교실) ;
  • 김범준 (중앙대학교 의과대학 피부과학교실)
  • Received : 2016.01.18
  • Accepted : 2016.05.27
  • Published : 2016.06.30

Abstract

Acne vulgaris is a chronic inflammatory condition characterized by comedo, papule, cyst, nodule and postinflammatory hyperpigmentation. Meanwhile, it is also induced by adverse event of drugs. Among them, acneiform folliculitis is a side effect of epidermal growth factor receptor (EGFR) inhibitor, which is an anticancer agent, and its incidence may occur in upward of 75 ~ 100% of cases. The main method of acne vulgaris treatment is oral antibiotics, retinoids, topical medication and so on. However, it is limitation that teratogenicity caused by retinoids and antibiotic resistance increased by using antibiotics. In this study, we aimed to evaluate the clinical efficacy and safety of topical recombinant human (rh) EGF in treating facial acne vulgaris. Twenty three Koreans (age: 10 ~ 29 years) with mild to moderate acne vulgar participated in the study and applied topical rhEGF cream (trouble control EGF) with 3 products (trouble control clarifying cleansing foam, trouble control all-clear filling toner, redroll calming moisture) on their face twice daily for four weeks. Several assessment methods were applied: Acne lesion counts score by investigator's global assessment, efficacy and satisfaction score by subjects. Skin sebum output level, hydration level and redness level were also measured at each visit. At the final visit, skin sebum level, transepidermal water loss, skin redness statistically decreased and acne lesions (comedone, papule) were statistically reduced. No severe side effects were observed during the study. In conclusion, topical rhEGF seems to be an effective and safe adjuvant treatment option for mild acne vulgaris.

여드름은 면포, 구진, 낭종, 결절, 색소 침착 등 다양한 피부병변으로 나타나는 모낭피지선의 만성 염증질환으로 사춘기부터 성인기까지 발생 연령대가 다양해지고 있다. 한편, 약물 부작용으로 여드름이 발생하기도 하는데, 표피성장인자(epidermal grouwth factor, EGF) 수용체 억제제 항암제를 사용할 경우 75 ~ 100%에서 여드름양 모낭염이 발생된다고 보고되고 있다. 여드름의 치료로 항생제, 레티노이드 경구 복용 및 외용 약제 도포 등 다양한 방법이 이용되고 있다. 그러나 최근 들어 레티노이드 기형 유발 가능성 및 Propionibacterium acne의 항생제 내성률 증가는 기존 치료의 한계로 여겨진다. 따라서 본 연구는 최근 여드름양 발진에 효과가 있다고 알려진 EGF를 함유한 외용제가 여드름 치료에 미치는 효과와 안정성을 평가하였다. 한국 성인 10 ~ 29세 23명을 대상으로 EGF 함유 제품(트러블컨트롤 EGF)과 3종 제품(트러블컨트롤 클래리파잉 클렌징폼, 트러블컨트롤 올-클리어 필링토너, 레드롤 카밍 모이스처)을 하루 두 번 사용하도록 하였다. 사용 후 영상 피지량, 경표피수분손실량, 피부 홍조 측정, 전문가 육안 평가, 사용 후 만족도 설문조사를 평가하였다. 최종 측정 시, 피부 피지량, 경피수분손실량, 피부 홍조가 통계학적으로 감소하였으며, 전문가 육안 평가에서 여드름 병변(면포, 구진)도 통계학적으로 감소하였다. 연구동안 심각한 부작용은 관찰되지 않았다. 표피성장인자 함유 외용제는 경도의 여드름에 안전하면서도 효과적으로 사용할 수 있을 것으로 생각된다.

References

  1. B. K. Ahn, S. J. Lee, K. Namkoong, Y. L. Chung, and S. H. Lee, Quality of life of acne patients, Korean J. Dermatol., 43(1), 6 (2005).
  2. A. Zaenglein, E. Graber, and D. Thiboutot, Acne vulgaris and acneiform eruptions, in : Fitzpatrick's dermatology in general medicine, eds. K. Wolff, L. Goldsmith, S. Katz, B. Gilchrest, A. Paller, and D. Leffell, 897, McGraw-Hill, New York (2008).
  3. A. Wollenberg, J. Kroth, A. Hauschild, and T. Dirschka, Cutaneous side effects of EGFR inhibitors-appearance and management, Dtsch. Med. Wochenschr., 135(4), 149 (2010).
  4. K. Busam, P. Capodieci, R. Motzer, T. Kiehn, D. Phelan, and A. Halpern, Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225, British J. Dermatol., 144(6), 1169 (2001). https://doi.org/10.1046/j.1365-2133.2001.04226.x
  5. T. Sato, N. Imai, and N. Akimoto, Epidermal growth factor and 1&agr;, 25-dihydroxyvitamin D3 suppress lipogenesis in hamster sebaceous gland cells in vitro, J. Invest. Dermatol., 117(4), 965 (2001). https://doi.org/10.1046/j.0022-202x.2001.01516.x
  6. J. U. Shin, J. H. Park, B. C. Cho, and J. H. Lee, Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor, Dermatology, 225(2), 135 (2012). https://doi.org/10.1159/000342203
  7. S. Cohen, Isolation of mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new born animal, J. Biol. Chem., 237(5), 1555 (1962).
  8. M. L. Kmiec, A. Pajor, and G. Broniarczyk-Dyla, Evaluation of biophysical skin parameters and assessment of hair growth in patients with acne treated with isotretinoin, Postepy. Dermatol. Alergol., 30(6), 343 (2013).
  9. M. R. Lee, C. B. Jeong, J. Y. Chul, H. K. Kim, and G. W. Nam, Correlation between skin translucency and scattering reflection using miniaturized new optical device, J. Soc. Cosmet. Sci. Kor., 37(2), 121 (2011).
  10. T. R. Mathanda, M. Bhat, R. P. Hegde, and S. Anand, Transepidermal water loss in neonates: baseline values using a closed-chamber system, Pediatr. Dermatol., 33(1), 33 (2016). https://doi.org/10.1111/pde.12704
  11. S. I. Jang, E. J. Kim, H. Park, H. J. Kim, J. M. Suk, B. J. Kim, J. H. Lee, and H. K. Lee, A quantitative evaluation method using processed optical images and analysis of age-dependent changes on nasolabial lines, Skin Res. Technol., 21(2), 201 (2015). https://doi.org/10.1111/srt.12177
  12. L. Nanney, Epidermal and dermal effect of epidermal growth factor during wound repair, J. Invest. Dermatol., 94(5), 624 (1990). https://doi.org/10.1111/1523-1747.ep12876204
  13. J. Baselag, Why the epidermal growth factor receptor? The rationale for cancer therapy, Oncologist., 7(4), 2 (2002).
  14. H. K. Kim, I. K. Yeo, K. Li, B. J. Kim, M. N. Kim, and C. K. Hong, Topical epidermal growth factor for the improvement of acne lesions: a randomized, double-blinded, placebo-controlled, split-face trial, Int. J. Dermatol., 53(8), 1031 (2014).
  15. R. S. Stern, When a uniquely effective drug is teratogenic, N. Engl. J. Med., 320(15), 1007 (1989).